Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555541 · ClinicalTrials.gov registry record · Phase 2
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by C. Babis Andreadis.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01555541 is a Phase 2 study that has completed, run by C. Babis Andreadis. The registered enrollment target is 19 participants.
The verdict
NCT01555541, a Phase 2 study, has completed, sponsored by C. Babis Andreadis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) and to examine its effectiveness in eliminating residual diffuse large B-Cell Lymphoma (DLBCL) in patients.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-05-25 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555541
The ClinicalTrials.gov registry entry for NCT01555541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. Babis Andreadis, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT01555541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555541 about?
NCT01555541 is a clinical study titled "Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma". The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) and to examine its effectiveness in eliminat...
What is the current status of trial NCT01555541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-05-25. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT01555541?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01555541?
This trial is sponsored by C. Babis Andreadis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.